Clinical effects investigation of cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling / 中国基层医药

ABSTRACT

Objective To investigate clinical effects and safety difference of cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling. Methods 240 elderly patients with coronary heart disease and poor lipid controlling were chosen and randomly divided into 3 groups including group A (80 patients)with atorvastatin for conventional dose,group B (80 patients)with atorvastatin for high dose and group C (80 patients)with atorvastatin for high dose associated with ezetimibe for cholesterol absorption inhibitor;and the compliance rate of total cholesterol (TC)and low density lipoprotein cholesterol (LDL-C),serum lipids before and after treatment and the incidence of adverse reaction of 3 groups were compared. Results The compliance rate of TC of group A,group B and group C were separately 40.00%(32/80),62.50%(50/80)and 96.25%(77/80);the compliance rate of LDL-C of group A,group B and group C were separately 51.25%(41/80),81.25%(65/80)and 98.75%(79/80);the compliance rate of TC and LDL-C of group C was significant better than that of group A and group B (χ2 =58.28,27.83,48.13,13.61,all P0.05).The incidences of adverse reaction of group A,group B and group C were separately 1.25%(1/80),3.75%(3/80)and 2.50%(2/80);there was no significant difference in incidence of adverse reaction among 3 groups(χ2 =1.03,P>0.05).Conclusion Cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling can efficiently control blood lipid levels,improve compliance rate of blood lipids,and did not increase the risk of adverse reaction.